Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Ovalicin is a natural sesquiterpene compound isolated from the fungus Pseudorotium ovalis and belongs to the class of cyclitols and tertiary alcohols[7][1][4]. It acts as a potent inhibitor of methionine aminopeptidase 2 (MetAP2), an enzyme involved in protein processing that regulates cell proliferation, angiogenesis, and lipid synthesis[10]. Through MetAP2 inhibition, ovalicin exhibits antiangiogenic activity—blocking new blood vessel formation—and has demonstrated antitumor effects in preclinical models[10][7]. Additionally, it shows antimicrosporidial activity against microsporidian infections in animal studies and is being explored for its potential as an antibiotic or anti-infective agent targeting various pathogens including fungi and viruses[5][2]. Ovalicin remains experimental with no current clinical approvals.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on ovalicin.